SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics,
Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of
central nervous system disorders, including obesity, today announced that the
Company will be presenting at the following upcoming investor conferences:
BioCentury Newsmakers in the Biotech Industry
Thursday, September 4, 2008, 10:00 AM Eastern time
Millennium Broadway Hotel, New York
UBS Global Life Sciences Conference
Tuesday, September 23, 2008, 9:30 AM Eastern time
Grand Hyatt Hotel, New York
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
development of pharmaceutical product candidates for the treatment of central
nervous system disorders, including obesity. The Company's lead combination
product candidates targeted for obesity are Contrave, which is in Phase III
clinical trials, and Empatic, which is in the later stages of Phase II
clinical development. Both product candidates take advantage of the Company's
understanding of how the brain appears to regulate appetite and energy
expenditure, as well as the mechanisms that come into play to limit weight
loss over time. Each product candidate is designed to act on a specific group
of neurons in the central nervous system with the goal of achieving appetite
suppression and sustained weight loss. Further information about the Company
can be found at http://www.orexigen.com.
.gif)
